Moxetumomab pasudotox in relapsed/refractory hairy cell leukemiaRobert J. Kreitman, Francis J. Giles, Claire Dearden et al.|Leukemia|2018Cited by 250
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.Patrizia Tosi, Michèle Cavo, Elena Zamagni et al.|PubMed|2002Cited by 111
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic SyndromesMaria Teresa Voso, Giuseppe Leone, Valeria Santini et al.|Clinical Cancer Research|2009Cited by 101
Differences among young adults, adults and elderly chronic myeloid leukemia patientsFabio Castagnetti, Mariella Girasoli, Gabriele Gugliotta et al.|Annals of Oncology|2014Cited by 99
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label studyPaola Tacchetti, Gianpietro Semenzato, Lucia Pantani et al.|The Lancet Haematology|2020Cited by 58